Max Healthcare Institute Limited
NSE: MAXHEALTH
Employs 16,334 permanent employees and workers, 8.1% on the year before, as filed for the year to 31 Mar 2026 on a group basis. Revenue in the quarter to 30 Jun 2026 was ₹783 cr.
Headcount
Annual, from the BRSR filed with NSE (as of 31 March each year)
| As of | Scope | Permanent | Change (%) | Contract / other | Change (%) |
|---|---|---|---|---|---|
| 31 Mar 2023 | Group | 10,424 | — | 4,693 | — |
| 31 Mar 2024 | Group | 12,337 | 1,913(18.4%) | 7,321 | 2,628(56.0%) |
| 31 Mar 2025 | Group | 15,114 | 2,777(22.5%) | 11,713 | 4,392(60.0%) |
| 31 Mar 2026 | Group | 16,334 | 1,220(8.1%) | 14,793 | 3,080(26.3%) |
Permanent = permanent employees + permanent workers, as defined in SEBI's BRSR. "Standalone" figures cover the listed company alone and exclude its subsidiaries.
Financials (₹ cr)
| Period | Revenue (₹ cr) | Change (%) | Employee cost (₹ cr) | Change (%) | Net profit (₹ cr) | Change (%) | Flags |
|---|---|---|---|---|---|---|---|
| Quarter ended 30 Jun 2026 | 783 | 50(6.8%) | 146 | 24(19.6%) | 168 | −36(17.5%) | |
| Quarter ended 31 Mar 2026 | 733 | 22(3.1%) | 122 | −3(2.6%) | 203 | 16(8.7%) | |
| Quarter ended 31 Dec 2025 | 711 | −26(3.5%) | 125 | −9(6.6%) | 187 | 27(16.5%) | |
| Quarter ended 30 Sept 2025 | 737 | 43(6.1%) | 134 | −1(0.7%) | 160 | −6(3.4%) | |
| Quarter ended 30 Jun 2025 | 694 | 35(5.4%) | 135 | 9(7.3%) | 166 | −11(6.4%) | |
| Quarter ended 31 Mar 2025 | 659 | −39(5.5%) | 126 | 3(2.6%) | 177 | 39(28.3%) | |
| Quarter ended 31 Dec 2024 | 697 | 11(1.7%) | 123 | −1(0.5%) | 138 | −93(40.2%) | |
| Quarter ended 30 Sept 2024 | 686 | 65(10.4%) | 123 | 4(3.6%) | 231 | 77(50.1%) | |
| Quarter ended 30 Jun 2024 | 621 | 11(1.8%) | 119 | 6(5.7%) | 154 | −88(36.3%) | |
| Quarter ended 31 Mar 2024 | 610 | 19(3.3%) | 113 | −1(0.7%) | 242 | 84(52.9%) | |
| Quarter ended 31 Dec 2023 | 591 | −6(1.0%) | 113 | −2(2.1%) | 158 | −3(2.0%) | |
| Quarter ended 30 Sept 2023 | 597 | 53(9.8%) | 116 | 9(8.8%) | 161 | 35(28.0%) | |
| Quarter ended 30 Jun 2023 | 544 | 36(7.2%) | 106 | 9(9.6%) | 126 | −0(0.3%) | |
| Quarter ended 31 Mar 2023 | 507 | 25(5.3%) | 97 | 3(2.6%) | 126 | 4(3.5%) | |
| Quarter ended 31 Dec 2022 | 482 | 8(1.7%) | 95 | 5(5.7%) | 122 | −237(65.9%) | ⚠ |
| Quarter ended 30 Sept 2022 | 474 | 48(11.2%) | 90 | 1(0.8%) | 359 | 273(320.6%) | |
| Quarter ended 30 Jun 2022 | 427 | 45(11.9%) | 89 | 16(21.4%) | 85 | 19(28.9%) | |
| Quarter ended 31 Mar 2022 | 381 | −17(4.2%) | 73 | −14(15.6%) | 66 | −38(36.3%) | ⚠ |
| Quarter ended 31 Dec 2021 | 398 | −52(11.6%) | 87 | −15(14.9%) | 104 | 31(41.7%) | ⚠ |
| Quarter ended 30 Sept 2021 | 450 | −50(10.1%) | 102 | −0(0.5%) | 73 | −15(16.7%) | ⚠ |
| Quarter ended 30 Jun 2021 | 500 | 169(51.2%) | 102 | 9(9.2%) | 88 | 81(1114.4%) | ⚠ |
| Quarter ended 31 Mar 2021 | 331 | −15(4.4%) | 94 | 5(5.5%) | 7 | −24(77.0%) | ⚠ |
| Quarter ended 31 Dec 2020 | 346 | 64(22.8%) | 89 | 31(53.3%) | 32 | 21(202.5%) | ⚠ |
| Quarter ended 30 Sept 2020 | 282 | — | 58 | — | 10 | — | ⚠ |
| Period ended 31 Dec 2025 | 2,142 | — | 395 | — | 513 | — | |
| Period ended 30 Sept 2025 | 1,431 | 517(56.5%) | 269 | 89(49.3%) | 326 | −119(26.8%) | |
| Period ended 30 Sept 2022 | 914 | — | 180 | — | 446 | — | |
| Year ended 31 Mar 2026 | 2,874 | 211(7.9%) | 517 | 26(5.2%) | 717 | 16(2.2%) | |
| Year ended 31 Mar 2025 | 2,664 | — | 491 | — | 701 | — |